Benzinga reports that a jury has handed a plaintiff a $8 billion verdict in a Risperdal lawsuit. Risperdal was approved for use in 1993. Many of the plaintiffs suing Johnson & Johnson say that the company failed to warn of the risk of gynecomastia.
On Wednesday, October 9th, a Philadelphia court ordered Johnson & Johnson to pay $8 billion in damages to a patient. The patient had previously been awarded $680,000 for the same claims. This case marks Johnson & Johnson’s second legal payout this month. On October 1st, the company agreed to pay $20 million to settle an opioid lawsuit with two counties in Ohio. The company is also under fire for its vaginal mesh, its Baby Powder, and it’ birth control implant, Essure.
Last month, a New Jersey court closed a trial by awarding a $37.3 million verdict. Johnson & Johnson intends to appeal the verdict on numerous grounds.
Risperdal is a prescription medication used to treat certain mental and mood disorders. Some of these disorders include schizophrenia, bipolar disorder, and irritability associated with autism disorder. The medication belongs to a class of medications known as antipsychotics. Risperdal has side-effects that include drowsiness, lightheadedness, dizziness, drooling, nausea, weight gain, and tiredness. However, in young male children, Risperdal can cause a condition known as gynecomastia, when a male begins to develop female breast tissue. According to some class action lawsuits, Johnson & Johnson did not strengthen labels to reflect this risk, despite doctors urging them to do so.
Have you been injured? We can help. Call today.